The present invention provides new salts and crystalline forms of leukadherin LA1 [(Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid] according to Formula I. Methods for preparation of the salts and crystalline forms are also described, as well as methods for treating 2 integrin-mediated diseases and conditions using the salts and crystalline forms.
本发明提供了新的盐和晶型形式的白细胞粘附素
LA1 [(Z)-4-(5-((3-苄基-4-氧代-2-
硫代
噻唑啉-5-基亚甲基)
呋喃-2-基)
苯甲酸],其
化学式为I。还描述了制备这些盐和晶型形式的方法,以及利用这些盐和晶型形式治疗2整合素介导的疾病和症状的方法。